As of Nov 15, 2024, Johnson & Johnson Intrinsic Value is $101.5. This suggests it may be overvalued by 34.1% compared to its current price of around $154.0.
As of Nov 15, 2024, Johnson & Johnson's Discounted Cash Flow (DCF) valuation estimates its share price at $42.2. This suggests it may be overvalued by 72.6% to its current price of around $154.0, using a discount rate of 7.0% and terminal growth rate of 3.0%.
Johnson & Johnson is currently considered overvalued based on its Discounted Cash Flow (DCF) valuation and Relative Valuation, which estimates its share price to be $101.5, compared to a market price of around $154.0. This suggests a potential overvaluation of 34.1%.